Trials / Recruiting
RecruitingNCT06358469
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 249 (estimated)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to answer the following question: Are there types of early-stage vulvar cancer that require either less or more treatment than the usual approach?
Detailed description
This study is being done to find out if these approaches are better or worse than the usual approach for early-stage vulvar cancer. The usual approach is defined as care most people get for early-stage vulvar cancer. The usual approach for patients who are not in a study is treatment with surgery. Tissue that is removed as part of this procedure is analyzed in the pathology laboratory to guide the doctor in deciding whether additional surgery should be recommended. For patients deciding to take part in this study, the treatment that will be recommended will be based on laboratory testing of the cancer. The laboratory assessments include a test to determine if the cancer is caused by the Human Papilloma Virus (HPV) or not caused by HPV. If the laboratory test results show the vulvar cancer is caused by HPV, the study doctor will recommend the patient participate in sub-study A. In sub-study A, the patient will receive no additional surgery (observation). If the laboratory test results show the vulvar cancer is not caused by HPV, the study doctor will recommend the patient participate in sub-study B. In sub-study B, patients will receive either a second surgery or no additional surgery (observation).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Surgery | Re-excision of vulvar cancer margin |
| OTHER | Active Surveillance | The investigator will follow the patient to watch for side effects and keep track of patient's health |
Timeline
- Start date
- 2024-12-10
- Primary completion
- 2030-06-30
- Completion
- 2031-11-30
- First posted
- 2024-04-10
- Last updated
- 2026-04-14
Locations
10 sites across 2 countries: Canada, New Zealand
Source: ClinicalTrials.gov record NCT06358469. Inclusion in this directory is not an endorsement.